No Data
Junshi Biosciences' Teplizumab Injection Included in China's 2025 Drug Insurance Catalog; Shares Up 6%
Express News | Shanghai Junshi Biosciences - Toripalimab Injection Were Successfully Included in Category B of National Drug List for Basic Medical Insurance
Junshi bio (688180.SH): Tuoyi's new indications included in the national medical insurance directory.
On November 28, Junshi Bio (688180.SH) announced that its product Toripalimab Injection (trade name: Tuoyi, product code: JS001) has successfully added 4 new indications to the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)" (referred to as the "National Medical Insurance List"). The new version of the National Medical Insurance List will be officially implemented starting from January 1, 2025. As of the date of this announcement, Tuoyi has all 10 indications approved in mainland China included in the National Medical Insurance List, making it the only drug in the National Medical Insurance List used for melanoma.
Dr. Reddy's Launches Toripalimab Immuno-oncology Drug in India
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Junshi Bio (688180.SH) signed a licensing agreement involving two dual-target fusion proteins for the treatment of malignant tumors.
Junshi bio (688180.SH) announced that recently, the company signed a "License Agreement" with the licensor; the licensor granted...
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%No Data
No Data
